ClearTrial announced it will demonstrate its Clinical Trial Operations (CTO) software to an audience of more than 125 clinical outsourcing professionals at the 3rd Annual Clinical Outsourcing World conference in London. The event attracts biopharm companies from around the globe to hear outsourcing experts discuss strategic and operational challenges of partnering with CROs.
ClearTrial software is built on an activity-based or “project management” architecture, which enables the software to provide speed, accuracy, and flexibility to outsourcing groups and clinical operations. Supporting all outsourcing models and contract types, as well as 39 currencies and over 150 therapeutic indications, the software automatically calculates labor costs across 70 different countries.
Cubist Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment, recently acquired the ClearTrial software, with a view to further enhance their clinical outsourcing efficiency.
“New clinical outsourcing models and alternatives that are in practice today have created much more complexity for our clinical trial planning and for optimizing our outsourcing needs,” said Dr. Santosh Vetticaden, Chief Medical Officer at Cubist. “We are looking forward to utilizing the capabilities of ClearTrial, to allow us to quickly compare cost scenarios for different approaches—fully outsourced, outsourced by function, independent contractors, and studies performed in whole or in part by internal Cubist personnel.”
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.